SCHEMBL3908491

SCHEMBL3908491

CC(=O)N1CC(=O)N(Cc2ccc(F)cc2)c2cccnc21

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
TSHR P16473 1/20 0.44
HDAC1 Q13547 2/20 0.39
HDAC6 Q9UBN7 2/20 0.39
TP53 P04637 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
PTGDR2 Q9Y5Y4 2/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 2/20 0.38
KAT2B Q92831 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
RIPK1 Q13546 1/20 0.37
THRB P10828 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3905855 0.92 CYP1A2 (0.45) CYP1A2CYP2C19MEN1KMT2ATSHR
SCHEMBL3908071 0.88 CYP1A2 (0.44) CYP1A2CYP2C19MEN1KMT2ATSHR
SCHEMBL3908495 0.84 KMT2A (0.53) MEN1KMT2ATSHRHDAC1HDAC6
SCHEMBL3908077 0.74 MEN1 (0.46) CYP1A2CYP2C19MEN1KMT2AHDAC1
SCHEMBL12443420 0.69 POLB (0.45) MEN1KMT2AALDH1A1
SCHEMBL8066621 0.68 CYP1A2 (0.49) CYP1A2CYP2C19MEN1KMT2ATSHR
SCHEMBL27616288 0.67 KMT2A (0.52) CYP1A2CYP2C19KMT2ATSHRMAPT
SCHEMBL4436008 0.67 BRD4 (0.47) MEN1KMT2ATSHRTP53SMN1; SMN2
SCHEMBL4899362 0.66 MEN1 (0.42) CYP1A2CYP2C19MEN1KMT2ATP53
SCHEMBL13893718 0.66 BRD4 (0.46) MEN1KMT2ATSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7517532-B2 Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors MERCK & CO., INC. (US) 2009-04-14 US disclosed
US-7517532-B2 Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors MERCK & CO., INC. (US) 2009-04-14 US disclosed
US-7517532-B2 Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors MERCK & CO., INC. (US) 2009-04-14 US disclosed
US-20060024330-A1 Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060024330-A1 Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors DHPS, DUT, CDKN1A CYP1A2 417/4885CYP2C19 918/4885MEN1 4191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.